Imbed Biosciences’ Clinical Successes to be Highlighted at SAWC Fall 2018
MADISON, WI, JULY 27, 2018
Microlyte® Matrix resorbable antimicrobial wound matrix, will be presented at the Fall Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV from November 2-4, 2018. The company will also have a presence in the exhibitor space at booth #104. SAWC is the nation’s largest interdisciplinary wound care forum.
SHARE THIS ARTICLE
The poster presentations, delivered by several of Imbed’s clinical collaborators, will highlight results in a variety of complex, chronic wounds and surgical applications. The clinical case series were conducted independently at Rush University Medical Center (Chicago, IL), East Tennessee State University (Johnson City, TN), Duke Wound Management Clinic (Durham, NC), and the Institute for Advanced Wound Care (Montgomery, AL), and typically evaluated wound closure after application of Microlyte® Matrix to diabetic wounds, leg ulcers, an infected surgical site, and a radiation wound. In one series, Microlyte® Matrix was also implanted in non-healing diabetic ulcers.
“The work that will be presented at SAWC represents a pivotal point for Imbed. We are excited to see positive clinical outcomes in the hands of skilled wound healing practitioners. We believe that these improved clinical outcomes will naturally lead to improved economic outcomes for small independent practices and large healthcare systems, alike” said Ankit Agarwal, President and CEO of Imbed Biosciences. “We are grateful to be working with collaborators who continually push the bounds of what we know Microlyte® Matrix can do.”
Additionally, prospective users who visit the SAWC exhibit hall will get an up-close look at Imbed’s groundbreaking, FDA-cleared Microlyte® Matrix resorbable antimicrobial wound matrix. Microlyte® Matrix is primarily composed of an ultrathin, resorbable polymeric film, which means it never needs to be removed from the wound bed. Microlyte® Matrix is also fully synthetic, so there is no risk of disease transmission from animal based-components and it has a long shelf-life (2 years or more) under ambient conditions. Microlyte® Matrix is cleared for application in acute wounds such as lacerations, skin tears, abrasions, surgical wounds (e.g., donor and graft sites, incisions), partial thickness first- and second-degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers. The product may be applied daily or up to every 3 days, depending on the wound and the healing progression. The duration of the treatment depends on wound type and healing conditions.
Poster presentations of interest include:
About Imbed Biosciences, Inc.
Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and soft-tissue repair. The company has a portfolio of products in development based on its patented Microlyte® Matrix polymeric multilayer platform that presents bioactive molecules on tissue surfaces to combat local pain and infections, support soft-tissue repair, and reduce antibiotic/opioid abuse. Imbed is backed by venture capital group WISC Partners based in Madison, WI, and has received research grants from the National Institutes of Health and the National Science Foundation. For more information, please visit www.www.imbedbio.com
SHARE THIS ARTICLE